Gattefossé

Abstract Mucopolysaccharidosis type I (MPS-I) is a rare, multisystemic lysosomal storage disease (LSD) caused by mutations in the IDUA gene, which encodes...

Abstract Purpose Simvastatin (SIM) is a widely prescribed lipid-lowering agent; however, its clinical efficacy is hindered by poor aqueous solubility...

The Oral Drug Delivery Landscape As drug discovery pushes into new therapeutic frontiers, the task of developing effective, patient-friendly oral...

Abstract High drug-loaded immediate-release formulations can be produced using a solvent-free and continuous melt-granulation method with a twin-screw extruder. Known...

Abstract Objective: This study aimed to develop an oral celastrol-loaded self-microemulsifying drug delivery system (Cel-SMEDDS) to enhance the therapeutic efficacy...

Abstract Entacapone is a catechol-O-methyltransferase (COMT) inhibitor, widely used for the symptomatic treatment of Parkinson’s disease. However, it presents setbacks...

by Gattefosse; original article first published at Drug Development and Delivery THE EVOLVING ROLE OF THE EXCIPIENT PARTNER The pharmaceutical...

Abstract Hygroscopicity poses a significant challenge in the formulation of pharmaceutical and nutraceutical products, as moisture absorption often leads to...

Abstract Tolcapone is a nitrocatechol-based drug used as adjuvant therapy in Parkinson’s Disease (PD). Despite being effective in managing PD-associated...

Abstract Background: Rebamipide (REB) is a poorly water-soluble drug with limited ocular bioavailability, necessitating advanced delivery strategies for sustained therapy in...